Form 4: Fairmount Funds Boosts Oruka Therapeutics Stake

Fairmount Funds Management and its affiliates acquired 333,340 shares of Oruka Therapeutics common stock in a private placement for $15 per share.

Summary

• Fairmount Funds Management LLC, along with Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P., acquired 333,340 shares of Oruka Therapeutics, Inc. common stock.
• The transaction occurred on September 17, 2025, at a price of $15 per share.
• The shares were purchased from Oruka Therapeutics in a private placement, which is exempt from Section 16(b) under Rule 16b-3(d)(1).
• Following this transaction, Fairmount Healthcare Fund II L.P. indirectly beneficially owns 1,131,954 shares, and Fairmount Healthcare Co-Invest III L.P. indirectly beneficially owns 2,573,308 shares.
• Fairmount Funds Management LLC, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.
• Peter Harwin, a Managing Member of Fairmount, serves on Oruka Therapeutics' board of directors, leading Fairmount to be deemed a director by deputization.

Sentiment

Score: 8

Explanation: The acquisition of a significant number of shares by a 10% owner and director in a private placement indicates strong insider confidence and provides capital to the company, which is a positive signal for investors.

Positives

• Significant acquisition of 333,340 shares by a 10% owner and director, indicating strong confidence in Oruka Therapeutics' future.
• The private placement provides Oruka Therapeutics with additional capital, strengthening its financial position.
• The transaction price of $15 per share provides a clear valuation point for this institutional investment.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding Oruka Therapeutics' future performance or strategic direction.

Management Comments

• Fairmount Funds Management LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

This private placement and insider buying activity by a significant institutional investor and director is common in the biotechnology sector, where companies often rely on strategic investments to fund research, development, and operational growth. Such investments can signal confidence in a company's pipeline or market potential.

Corporate Governance

Related Party Transactions

• The acquisition of 333,340 shares of common stock by Fairmount Funds Management LLC and its affiliates from Oruka Therapeutics in a private placement constitutes a related party transaction, given Fairmount's status as a 10% owner and its representative (Peter Harwin) on the board of directors.

Stakeholder Impact

• Shareholders: The capital infusion from the private placement and the vote of confidence from a significant institutional investor could positively impact shareholder sentiment and potentially the stock price.
• Company: The capital raised provides funding for operations, research, and development, supporting the company's strategic objectives.

Key Dates

Recommendation

The significant acquisition of shares by a 10% owner and director, Fairmount Funds Management, in a private placement at a fixed price of $15 per share signals strong insider confidence in Oruka Therapeutics. This institutional buying, coupled with the capital infusion for the company, suggests a positive outlook and could be a catalyst for future share price appreciation, making it an attractive 'buy' for seasoned investors.

Keywords

Oruka Therapeutics, ORKA, Fairmount Funds Management, Insider Buying, Private Placement, Equity Acquisition, SEC Form 4, Beneficial Ownership, Biotechnology, Healthcare Investment